South Asian Journal of Cancer最新文献

{"title":"Understanding Cancer Epidemiology in Himachal Pradesh, India.","authors":"Randhir Singh Ranta, Sakshi Sharma, Manoj Chauhan","doi":"10.1055/s-0044-1790222","DOIUrl":"10.1055/s-0044-1790222","url":null,"abstract":"<p><strong>Objective: </strong>This study investigated the distribution of cancer cases across different age groups, sexes, and regions in Himachal Pradesh, India, with the aim of informing targeted public health strategies.</p><p><strong>Materials and methods: </strong>Cancer incidence data were collected from various age groups, sexes, and blocks.</p><p><strong>Statistical analysis: </strong>Chi-square tests were used to assess the significance of differences in cancer patient distribution according to age, sex, and region.</p><p><strong>Results: </strong>Cancer incidence increased with age, peaking in the 58 to 67 years age group. The highest number of patient was reported, particularly among individuals aged 38 years and above. Minimal cases were observed in the youngest age groups (< 17 and 18-27 years), while a significant increase was noted in the middle age groups (28-57 years). Cancer cases were nearly equally distributed between males (50.1%) and females (49.9%). A chi-square value of 180.18 indicated a statistically significant difference in cancer incidence according to age and sex. Gender-specific trends revealed higher cancer incidences in females during middle age (28-57 years) and in males during older age (58 years and above). The highest number of cases was 18.1%, followed by 14.7 and 14.6%, while the lowest incidence was 1.5%.</p><p><strong>Conclusion: </strong>The present study underscores the need for comprehensive and targeted public health strategies to manage cancer burdens effectively. Focusing on high-incidence regions and ensuring equitable health care access for all genders can improve cancer outcomes and reduce mortality rates associated with the disease.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"86-89"},"PeriodicalIF":0.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Budding: A Novel Prognostic Marker in Breast Carcinoma with Correlation of Histopathological and Immunohistochemical Parameters.","authors":"Poornima Manimaran, Ashini Shah, Amisha Gami, Jahnavi Gandhi, Sneha Kakoty, Varnika Rai, Priti P Trivedi","doi":"10.1055/s-0044-1789582","DOIUrl":"10.1055/s-0044-1789582","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is a highly heterogenous tumor with different subtypes showing varying prognosis. Tumor budding is an unfavorable histological feature of many epithelial cancers. The purpose of this study is to analyze the association between tumor bud density with various histological and immunohistochemical characteristics and to explore its prognostic role in breast carcinoma.</p><p><strong>Materials and methods: </strong>A retrospective analysis was performed on 100 patients of breast cancer diagnosed in our institute from January to December 2017. Hematoxylin and eosin (H&E) stained slides from tumors and immunohistochemical slides were reviewed independently by two pathologists, and clinical data were acquired from computerized records. Patients on neoadjuvant chemotherapy were excluded from the study.</p><p><strong>Results: </strong>The study comprised 100 patients of invasive breast carcinoma. The median age was 52 years, and 96% were invasive ductal carcinoma. The median follow-up was 34 months. High tumor bud density was substantially correlated with primary tumor staging (T3, T4; 73% [11/15] cases) and lymph node staging (N2, N3; 68% [13/19] cases) with <i>p</i> -values of 0.017 and 0.023, respectively. Systemic metastasis (85% [6/7] cases) was significantly associated with high tumor bud density ( <i>p</i> =0.025) but lymphovascular invasion (LVI) and perineural invasion (PNI) were not significantly associated with tumor bud density ( <i>p</i>  = 0.762 and 0.862, respectively). Patients with N2 nodal stage had low event-free survival rate than N0/N1 nodal stage irrespective of tumor bud status. Grade 3 tumors with high tumor bud density had worse event-free survival than any other grades. There was no association of tumor bud density with tumor staging, necrosis, PNI, LVI, estrogen receptor (ER), progesterone receptor (PR) and <i>Her2/neu</i> , and event-free survival.</p><p><strong>Conclusion: </strong>Strong relationships have been found between tumor bud density and poor prognostic variables such as primary tumor staging and lymph node staging. These results provide credence to the idea that tumor bud density can be an assessable prognostic feature that should be taken into account while reporting breast cancer cases. Tumor bud density evaluation has to be standardized nevertheless if it is to be widely adopted.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"38-44"},"PeriodicalIF":0.6,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal Carcinoma: Is There Any Correlation between Her2/neu Expression, Ki-67 Score, and Tumor Budding and Clinicopathological Parameters?-A Prospective Institution-Based Study.","authors":"Susnata Khan, Senjuti Dasgupta, Asit Ranjan Deb","doi":"10.1055/s-0044-1789276","DOIUrl":"10.1055/s-0044-1789276","url":null,"abstract":"<p><strong>Objectives: </strong>Colorectal cancer is one of the most frequent cancers worldwide and is still a major cause of cancer mortality. Her2/neu, Ki67 score, and tumor budding are independent prognostic factors in colorectal carcinomas. The objectives of the study were to evaluate Her2/neu expression, Ki67 score, and tumor budding index at invasive margin in colorectal carcinoma and find out their possible correlations with different clinicopathological factors.</p><p><strong>Materials and methods: </strong>An institution-based observational cross-sectional study was conducted for 18 months. Forty-one patients with histologically proven diagnosis of colorectal carcinoma were included. Histopathological and immunohistochemical analyses (Her2/neu and Ki-67) of each case were done.</p><p><strong>Statistical analysis: </strong>Data analysis was done using the SPSS software.</p><p><strong>Results: </strong>A significant correlation was found between tumor budding status and pathological T stage, Dukes' and American Joint Committee on Cancer stages, and between tumor-infiltrating lymphocytes status and Ki-67 expression status ( <i>p</i>  < 0.05).</p><p><strong>Conclusion: </strong>The prognostic importance of tumor budding in colorectal carcinoma is very clear. Considering the small sample size of the present study, the prognostic values of Her2/neu and Ki-67 are required to be explored further in larger cohorts in the future.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"320-324"},"PeriodicalIF":0.6,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing Cervical Cancer Screening: Self-Vaginal Sampling for Human Papillomavirus Detection.","authors":"Bhagyashri R Patil-Takbhate, Swati D Bhakare","doi":"10.1055/s-0044-1789274","DOIUrl":"10.1055/s-0044-1789274","url":null,"abstract":"<p><p>Self-vaginal sampling (SVS) is a promising tool for cervical cancer prevention, offering a convenient and cost-effective alternative to traditional screening. With an 80% lifetime risk of HPV infection among women, SVS improves accessibility, particularly for marginalized communities and older women who are often excluded from routine screening. It reduces discomfort, empowers self-care, and provides insights into the vaginal microbiome, aiding in the detection of pathogens beyond HPV. However, challenges such as loss to follow-up, sampling errors, and misconceptions persist. Despite these hurdles, SVS remains a vital strategy for increasing screening participation and reducing cervical cancer disparities.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"67-68"},"PeriodicalIF":0.6,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Low-Dose Nivolumab in Treatment of Advanced Solid Tumors: A Retrospective Audit from Resource-Constrained Settings.","authors":"Amit Kumar, Akhil Kapoor, Vanita Noronha, Vijay M Patil, Amit Joshi, Nandini Menon, Amit Janu, Abhishek Mahajan, Akhil Rajendra, Amit Agarawal, Satvik Khaddar, Anu Rajpurohit, Lakhan Kashyap, Anne Srikant, Gautam Panda, Kishore Kumar Kota, Vikas Talreja, Kumar Prabhash","doi":"10.1055/s-0044-1788649","DOIUrl":"10.1055/s-0044-1788649","url":null,"abstract":"<p><strong>Background: </strong>Immunotherapy has improved outcomes in many advanced solid tumors. In resource-constrained settings, less than 2% of patients can afford standard dose immunotherapy. A recent phase II study showed the efficacy of low-dose immunotherapy in this setting. We used low-dose immunotherapy on a compassionate basis in patients who had progressed on available standard treatment options and standard dose immunotherapy was not feasible.</p><p><strong>Patients and methods: </strong>We retrospectively collected data from the medical oncology department for consecutive patients who had initially received standard lines of therapy followed by low-dose immunotherapy (nivolumab 40 mg) on a compassionate basis. The demographic details, histology, prior treatment, clinical and radiological response, date of disease progression, date of death, and toxicity data were collected.</p><p><strong>Results: </strong>A total of 54 consecutive patients, who received low-dose immunotherapy with nivolumab from January 1, 2018 to February 14, 2020, were included in this analysis; 4 patients were not radiologically evaluable. The median age was 50.4 years (range 35-74 years), male:female ratio was 6:1. The most common comorbidities were hypertension and diabetes seen in 12 (22.2%) and 6 (11.1%) patients, respectively. The majority of the patients (70.4%) were of head and neck cancer. The median follow-up was 4.5 months (range 0.5-11.7). Clinical benefit was observed in 18 (33.3%) patients. Partial response and stable disease were achieved in 9 (16.7%) and 5 (9.3%) patients, respectively. Median survival was not reached for these patients. Six months progression-free survival and overall survival were 100 versus 8.7% (hazard ratio [HR] 0.05, 95% confidence interval [CI]: 0.01-0.36; <i>p</i>  = 0.003) and 100 versus 29.7% (HR 0.03, 95% CI: 0.00-0.95; <i>p</i>  = 0.047), respectively, for responders and nonresponders. The side effects were manageable.</p><p><strong>Conclusion: </strong>In resource-constrained settings, low-dose immunotherapy with nivolumab seems to be an effective treatment option. Further studies are warranted to evaluate this approach.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"70-76"},"PeriodicalIF":0.6,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Applicability of Tumor Budding and Poorly Differentiated Clusters as Additional Prognostic Markers in Colorectal Cancers.","authors":"Sagarika Sarkar, Rena Guha, Sudipta Chakrabarti","doi":"10.1055/s-0044-1788050","DOIUrl":"10.1055/s-0044-1788050","url":null,"abstract":"<p><strong>Purpose: </strong>Very few studies have assessed tumor budding (TB) and poorly differentiated cell clusters (PDCs) simultaneously in colorectal cancers (CRCs). The goal of this study was to establish a correlation between these two pertinent histological features and to reinforce the importance of their incorporation in routine histopathological reporting of CRC cases as a means to predict clinical outcome.</p><p><strong>Methods: </strong>Resection specimens of colorectal carcinoma were included in the study. Patients who received presurgical therapy, or refused consent were excluded. PDC and TB were evaluated in routine hematoxylin and eosin-stained histopathological sections taken from the advancing edge of the tumor. TB and PDC were reported by selecting a \"hotspot\" chosen after review of all available slides with invasive tumor. It was then followed by their correlation with other known prognostic factors.</p><p><strong>Results: </strong>Spearman's rho calculator for strength of association between TB and PDC as well as association of TB and PDC individually with known prognostic factors revealed statistical significance. Correlation of TB and PDC with histologic grade, primary tumor (pT), and regional lymph node (pN) stage was done based on one-way analysis of variance calculator, which yielded statistically significant results.</p><p><strong>Conclusion: </strong>Evaluation of these two histological parameters in the same hotspot field at the tumor invasive front plays a fundamental role in the definition of cancer aggressiveness and prediction of tumor behavior.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"315-319"},"PeriodicalIF":0.6,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Staging and Management of Cervical Cancer at the Colposcopy Clinic of Bangabandhu Sheikh Sheikh Mujib Medical University (BSMMU), Bangladesh.","authors":"Ashrafun Nessa, Thrina Islam, Noor-E-Ferdousi Noor-E-Ferdousi, Anjuman Sultana, Kamrul Hasan Khan, Harun Ur Rashid","doi":"10.1055/s-0043-1776288","DOIUrl":"10.1055/s-0043-1776288","url":null,"abstract":"<p><p>Anjuman SultanaCervical cancer (CC) ranks as the second most common cancer among women in Bangladesh. Unfortunately, due to late-stage diagnosis and inadequate treatment facilities, the mortality rate remains high. The stage at which CC is diagnosed plays a crucial role in predicting a woman's survival. This study aimed to determine the staging patterns of CC at presentation in the colposcopy clinic of Bangabandhu Sheikh Mujib Medical University (BSMMU) and the subsequent management provided to these women. This retrospective study was conducted at the BSMMU colposcopy clinic from January 2019 to June 2020. It included CC cases with known staging, spanning from January 2016 to June 2019. Data were collected from the colposcopy registry book, telephone interviews, and face-to-face discussions during follow-up appointments. The mean age of women diagnosed with CC was 48.59 years (±2 standard deviations). Among the 523 women studied, 107 (20.5%) were diagnosed at stage I, 124 (23.7%) at stage IIA, 240 (45.9%) at stage IIB, while the remaining 52 (9.90%) were diagnosed with Stage III and IV disease. Within the study population, 39 (7.5%) women underwent radical hysterectomy alone, 110 (21.00%) underwent radical hysterectomy followed by adjuvant therapy, and 184 (35.14%) received primary radiotherapy or concurrent chemoradiation. A significant portion of CC cases presented at an early stage, underscoring the importance of an effective screening program to prevent advanced-stage disease and enhance early detection rates. Establishing a patient navigation system immediately after diagnosis is crucial to prevent the loss of follow-up and ensure timely treatment. It is imperative to enhance the healthcare system's capacity to ensure timely treatment for cancer patients.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 1","pages":"17-26"},"PeriodicalIF":0.5,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimation of Hand Function Impairment in Breast Cancer Survivors with Lymphedema.","authors":"Sandeep B Shinde, Pooja P Jain, Diksha S Jagwani, Sanjay K Patil, Anand Gudur, Ravindra V Shinde","doi":"10.1055/s-0044-1779301","DOIUrl":"10.1055/s-0044-1779301","url":null,"abstract":"<p><p>Breast cancer (BC) is one of the most frequent cancers in women, and breast cancer-related lymphedema (BCRL) is a common side effect of BC treatment. When the lymphatic drainage system is damaged, lymphedema develops, which further exacerbates swelling and leads to pain, an increase in limb circumference, a reduction in joint range of motion, and a decrease in the use of the affected hand for functional tasks. Handgrip strength is essential for performing upper limb functional daily activities. Less is known about the long-term effects of lymphedema on hand function. The objective of the study was estimation of hand function impairment in BC survivors with lymphedema. This study was carried out by randomly selecting 100 out of 1,200 women with lymphedema, aged between 40 and 80 years, and who underwent sentinel lymph node biopsy along with radiotherapy, were included in this study. The handgrip strength was tested using an electronic handheld dynamometer. The functional wrist and hand scales were used to evaluate hand function. The Michigan Hand Outcome Questionnaire (MHQ) was used to evaluate the hand's overall function. A statistical analysis was done using SPSS statistical software (version 23.0). Handgrip strength of the affected hand by BCRL when compared with the unaffected hand was reduced. Functional hand and wrist scale have shown very poor results of the affected hand when compared with the unaffected hand. Majority of participants in the MHQ were unsatisfied with the overall functioning of the hand ( <i>p</i>  < 0.0001). This study concluded that there was significant hand function impairment in BC survivors with lymphedema. BCRL had a negative impact on daily activities of the individual and also affected the mental, emotional, and social aspects. BCRL also had an impact on overall self-reported physical function and quality of life.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"23-29"},"PeriodicalIF":0.6,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal Origin: A Marker of Favorable Outcome in Krukenberg Tumor? Results from Clinical and Prognostic Analysis.","authors":"Purnima Thakur, Mukesh Sharma, Ashish Chauhan, Kapil M Pal, Shabnam Thakur, Manish Gupta, Shilpa Kaushal","doi":"10.1055/s-0043-1776789","DOIUrl":"10.1055/s-0043-1776789","url":null,"abstract":"<p><p>Purnima Thakur This study aimed to identify the prognostic factors affecting the survival of patients suffering from Krukenberg tumor (KT) and also to determine the survival in these patients. A retrospective review of patients diagnosed with KT between January 2015 and December 2021 was conducted at a tertiary cancer center. Clinicopathological variables were scrutinized, and survival analysis was performed. Thirty-six patients were enrolled in this study. The median age at diagnosis was 48 years (ranging from 22 to 71 years). The median overall survival (OS) was 9.9 months (95% confidence interval [CI]: 6.6 to 13 months). The mean OS for tumors originating in the colorectal region was longer compared to that for tumors of other sites (15.4 vs. 9 months, respectively; <i>p</i>  = 0.048). In univariate analysis, patients who received chemotherapy had better survival, while those presenting with ascites had a poor prognosis. No correlation was observed between age, menstrual status, bilaterality, size of ovarian metastases, extent of metastatic disease, metastasectomy, and survival. Multivariate Cox regression analysis showed that chemotherapy predicted a favorable survival outcome (hazard ratio [HR] = 0.200, 95% CI: 0.046-0.877, <i>p</i> -value = 0.033). KT is an aggressive tumor with a median OS of less than a year. Chemotherapy may improve survival. Patients with a primary tumor in the colorectal region have a better outcome, while those presenting with ascites indicate a poor prognosis.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 2","pages":"99-105"},"PeriodicalIF":0.6,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Level III Dissection in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy-A Prospective Study.","authors":"Rexeena V Bhargavan, Nisha Prasannan, K M Jagathnath Krishna, Paul Augustine, Kurian Cherian","doi":"10.1055/s-0043-1777727","DOIUrl":"https://doi.org/10.1055/s-0043-1777727","url":null,"abstract":"<p><p>Nisha Prasannan Breast cancer is the most common female cancer in India, with a significant number presenting as locally advanced breast cancer (LABC). Level III clearance is routinely performed in our institute in LABC following neoadjuvant chemotherapy (NACT). In our previous retrospective study, level III positivity rate was 15.5%. We aim to prospectively assess level III positivity rate in LABC patients post-NACT. This is a prospective study of female patients with LABC (defined as cT3N1-3M0 or cT4N0-3M0 or cT _any N2,3M0) who received NACT and underwent surgery including level III dissection from November 2019 to October 2021. Data collected included age, menopausal status, TNM stage at presentation, grade, hormone receptor and HER2 status, treatment response, ycT and ycN stage, and final histopathology. Univariate and multivariate analysis was undertaken. <i>p</i> -Value less than or equal to 0.05 was considered significant. Study recruited 598 patients. Level III node positivity rate was 8.4%. The clinical complete response rate (cCR) was 36% (215/598). On univariate analysis, significant association was present between level III node and cCR ( <i>p</i>  < 0.01), ycT0 stage ( <i>p</i>  = 0.001), ycN0 stage ( <i>p</i>  = 0.028), level II node positivity ( <i>p</i>  = 0.001), ypT stage ( <i>p</i>  = 0.001), and ypN stage ( <i>p</i>  = 0.001). On multivariate analysis, significant association was present between level III node and ycT stage ( <i>p</i>  < 0.001), ypT stage ( <i>p</i>  = 0.001), and ypN stage ( <i>p</i>  = 0.001). Level III positivity rate in LABC post-NACT is high. In patients with advanced ycT stage, it would be advisable to offer complete axillary dissection including level III. Level III dissection may be avoided in patients with ycT0 or ycN0 or with cCR.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 3","pages":"170-176"},"PeriodicalIF":0.6,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}